AbbVie (ABBV) Cash & Current Investments (2012 - 2026)
AbbVie (ABBV) reported Cash & Current Investments of $9.4 billion for Q1 2026, up 81.43% year-over-year from $5.2 billion in Q1 2025, and up 78.64% on a QoQ basis from $5.3 billion in Q4 2025.
AbbVie (ABBV) has 15 years of Cash & Current Investments data on file, last reported at $9.4 billion in Q1 2026.
- Quarterly Cash & Current Investments rose 81.43% year-over-year to $9.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 billion (up 81.43% YoY) and the FY2025 annual result came in at $5.3 billion, down 5.36% from the prior year.
- Cash & Current Investments climbed to $9.4 billion in Q1 2026 per ABBV's latest filing, from $5.3 billion in the prior quarter.
- Across five years, Cash & Current Investments topped out at $18.1 billion in Q1 2024 and bottomed at $5.2 billion in Q1 2025.
- The 5-year median for Cash & Current Investments is $8.8 billion (2023), against an average of $9.2 billion.
- The widest annual swing landed in 2024, when Cash & Current Investments soared 168.8%; it then slumped 71.35% in 2025.
- Tracing ABBV's Cash & Current Investments over 5 years: stood at $9.2 billion in 2022, then jumped by 38.87% to $12.8 billion in 2023, then tumbled by 56.66% to $5.6 billion in 2024, then decreased by 5.36% to $5.3 billion in 2025, then jumped by 78.64% to $9.4 billion in 2026.
- Per Business Quant, the three latest ABBV Cash & Current Investments figures stand at $9.4 billion (Q1 2026), $5.3 billion (Q4 2025), and $5.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 22.05 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 10.49 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 4.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.39 Bn |
| Dec 31, 2025 | 5.26 Bn |
| Sep 30, 2025 | 5.67 Bn |
| Jun 30, 2025 | 6.47 Bn |
| Mar 31, 2025 | 5.18 Bn |
| Dec 31, 2024 | 5.56 Bn |
| Sep 30, 2024 | 7.29 Bn |
| Jun 30, 2024 | 13.16 Bn |
| Mar 31, 2024 | 18.07 Bn |
| Dec 31, 2023 | 12.82 Bn |
| Sep 30, 2023 | 13.29 Bn |
| Jun 30, 2023 | 8.77 Bn |
| Mar 31, 2023 | 6.72 Bn |
| Dec 31, 2022 | 9.23 Bn |
| Sep 30, 2022 | 11.88 Bn |
| Jun 30, 2022 | 9.96 Bn |
| Mar 31, 2022 | 7.57 Bn |
| Dec 31, 2021 | 9.83 Bn |
| Sep 30, 2021 | 12.25 Bn |
| Jun 30, 2021 | 8.60 Bn |
| Mar 31, 2021 | 9.78 Bn |
| Dec 31, 2020 | 8.48 Bn |
| Sep 30, 2020 | 7.95 Bn |
| Jun 30, 2020 | 6.04 Bn |
| Mar 31, 2020 | 41.14 Bn |
| Dec 31, 2019 | 39.92 Bn |
| Sep 30, 2019 | 10.65 Bn |
| Jun 30, 2019 | 5.42 Bn |
| Mar 31, 2019 | 5.23 Bn |
| Dec 31, 2018 | 8.06 Bn |
| Sep 30, 2018 | 8.79 Bn |
| Jun 30, 2018 | 3.74 Bn |
| Mar 31, 2018 | 9.47 Bn |
| Dec 31, 2017 | 9.79 Bn |
| Sep 30, 2017 | 9.55 Bn |
| Jun 30, 2017 | 7.21 Bn |
| Mar 31, 2017 | 6.25 Bn |
| Dec 31, 2016 | 6.42 Bn |
| Sep 30, 2016 | 7.95 Bn |
| Jun 30, 2016 | 8.00 Bn |
| Mar 31, 2016 | 8.60 Bn |
| Dec 31, 2015 | 8.41 Bn |
| Sep 30, 2015 | 9.25 Bn |
| Jun 30, 2015 | 8.28 Bn |
| Mar 31, 2015 | 7.92 Bn |
| Dec 31, 2014 | 8.37 Bn |
| Sep 30, 2014 | 7.73 Bn |
| Jun 30, 2014 | 10.25 Bn |
| Mar 31, 2014 | 9.10 Bn |
| Dec 31, 2013 | 9.90 Bn |
| Sep 30, 2013 | 9.60 Bn |
| Jun 30, 2013 | 8.75 Bn |
| Mar 31, 2013 | 7.48 Bn |
| Dec 31, 2012 | 7.98 Bn |
| Sep 30, 2012 | 2.76 Bn |
| Jun 30, 2012 | 74.00 Mn |
| Mar 31, 2012 | 41.00 Mn |